Generic filters
Filter by content type
Taxonomy terms

WINT – Windtree Therapeutics Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 3

Low: 3

High: 3

Total Analysts: 2

Company Profile

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of therapeutics intended to address significant unmet medical needs. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Its Cardiovascular Program’s products candidates include Istaroxime, Oral SERCA2a Activators and Rostafuroxin. Its Pulmonary Program’s product candidates include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on ADS technology). The Company’s lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure (AHF) with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and is under phase II clinical trials.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan